Hong Kong Media Stock News

China Modern Dairy Holdings (SEHK:1117) has drawn fresh attention after recent share price moves, with the stock closing at HK$1.645 and showing mixed short term returns alongside strong multi year total return figures. The recent move to HK$1.645 follows a strong 90 day share price return of 66.16% and a 1 year total shareholder return of 29.53%. This suggests momentum around China Modern Dairy Holdings has been building as investors reassess both growth prospects and risks. Compare how...

SJM Holdings Limited was removed from the FTSE All-World Index (USD) on 19 September 2026, a shift that can influence how global index trackers and benchmarked investors view the stock within diversified portfolios. This exit from a major global benchmark may prompt some passive funds to sell SJM Holdings, which can affect liquidity, ownership mix, and market perception of the business fundamentals behind its casino and hospitality operations. Attention now turns to how SJM Holdings' removal...

The Asian markets have been navigating a complex landscape marked by fluctuating oil prices and evolving monetary policies, with investors keenly watching for signs of stability amid regional economic shifts. In this environment, identifying undervalued stocks can offer strategic opportunities for investors seeking to capitalize on potential growth in the region.

As September 2026 unfolds, the Asian markets are navigating a complex landscape marked by fluctuating oil prices and central bank rate hikes, with Japan's stock indices experiencing gains amid easing concerns over Middle East supply disruptions. In this environment of volatility and opportunity, identifying promising stocks requires a focus on companies that demonstrate resilience and adaptability in the face of economic shifts.

United Laboratories International Holdings reported that its subsidiary has dosed the first participant in two Phase III UBT251 studies in China, testing a long-acting GLP-1/GIP/GCG triple agonist for adults with type 2 diabetes across placebo and semaglutide controlled designs. The drug is already cleared for clinical trials in China and the United States across several metabolic indications and has been out-licensed to Novo Nordisk, which reinforces the commercial relevance of UBT251 in...

Air China reported August 2026 operating data, including 36,577.6 million available seat kilometers, 32,064.0 million revenue passenger kilometers, an 87.7% passenger load factor, and 16,683,300 passengers flown, alongside detailed cargo and overall load metrics. The carrier’s year to date figures show 252,904.7 million available seat kilometers and 215,478.2 million revenue passenger kilometers, with an 85.2% passenger load factor that gives investors a view of how Air China is filling its...

Wharf Real Estate Investment (SEHK:1997) has put cash returns front and center after announcing a first interim dividend of HK$0.94 per share, up from HK$0.66 a year earlier. That cash signal comes after a sharp 90 day share price return of 42.96% and a year to date gain of 20.76% at a latest share price of HK$30.48. The 1 year total shareholder return of 36.81% points to momentum that has been building rather than fading. Scan for other income focused real estate plays showing strong cash...

Weichai Power (SEHK:2338) has put two investor focused decisions on the table: a new cash dividend for H shares and a supplemental sales agreement with Shaanxi Automotive. Together, these moves reshape both cash flows and commercial ties. Weichai Power’s share price has pulled back over the past month, with a 30 day share price return of a 5.15% decline and a 90 day share price return of a 22.68% decline. However, the year to date share price return of 67.02% and a 1 year total shareholder...

Meitu (SEHK:1357) has pushed its AI ambitions further with MVLAND Version 2.0, introducing a new Studio Mode that integrates music analysis, storytelling tools, and detailed shot-level video controls for creators. The MVLAND upgrade comes at a tricky moment for Meitu shareholders. The stock closed at HK$4.035 after a 1-day share price gain of 5.77%. However, the 30-day share price return is down 8.92% and the year-to-date share price return has fallen 45.69%, while the 5-year total...

Some Maiyue Technology Limited ( HKG:2501 ) shareholders may be a little concerned to see that the Co-CEO & Executive...

Readers hoping to buy Lee's Pharmaceutical Holdings Limited ( HKG:950 ) for its dividend will need to make their move...

Longfor Group Holdings reported unaudited August 2026 figures, with contracted sales of RMB 2.20b on 250,000 sqm and year-to-date contracted sales of RMB 20.84b on 2,239,000 sqm, alongside RMB 18.18b of aggregated revenue excluding tax from property operation and property service. The split between approximately RMB 9.73b of operating income and RMB 8.45b of service income reflects how Longfor Group Holdings relies on both property sales and recurring services as key pillars of its business...

Shanghai Henlius Biotech (SEHK:2696) drew attention after regulators in mainland China accepted its New Drug Application for HLX14, a denosumab biosimilar targeting cancer related bone disease and giant cell tumor of bone. The regulatory progress comes as Shanghai Henlius Biotech’s 1-day share price return of 2.23% contrasts with a 7-day decline of 5.24% and a 30-day drop of 12.97%. The year-to-date share price return of 1.88% sits beside a 1-year total shareholder return that declined 23.07%...

Investors who take an interest in PATEO CONNECT Technology (Shanghai) Corporation ( HKG:2889 ) should definitely note...

China Reinsurance (Group) held a board meeting on 6 September 2026 to review a general mandate for new share issuance, a domestic share placement to a specific investor, related authorisations, and a conditional share subscription agreement. The focus on authorising fresh equity and a targeted domestic investor highlights how China Reinsurance (Group) may adjust its capital mix and shareholder base to support operating priorities in reinsurance, climate risk cover, and EV-related...

Amidst a backdrop of mixed performance across global markets, Asian equities have shown resilience with notable activity in technology and energy sectors. While the term "penny stock" might evoke images of speculative ventures from yesteryears, it still captures the essence of smaller or emerging companies that can offer substantial value when underpinned by strong financials. By focusing on balance sheet strength and growth potential, investors can uncover promising opportunities in these...

China Resources Power Holdings: Renewable output picks up pace China Resources Power Holdings (SEHK:836) has released new figures, with August and year-to-date operating data indicating higher total power generation and faster growth from its wind and solar subsidiaries. China Resources Power Holdings shares trade at HK$18.89 and the stock has built a steady positive trend, with a 30-day share price return of 5.53% and a 1-year total shareholder return of 10.41%. The 3-year total shareholder...

Shenzhen HQVT Technology (SEHK:1392) has drawn attention after a sharp move in the share price over the past week. This invites a closer look at how its AI-focused business profile lines up with recent trading. Recent trading has been intense. Shenzhen HQVT Technology's share price return over the past week sits at 95.59%, on top of a 30 day share price return of 78.43% and a year to date share price return of 39.40%. This points to rapidly building momentum rather than a slow grind...

Shanghai Electric Group (SEHK:2727) recently secured a full EPC turnkey contract and a 25-year service agreement for Unit 3 of the Sarawak Samalaju CCGT Project in Malaysia, highlighting its overseas high-end energy ambitions. Recent trading reflects that mix of excitement and caution. Shanghai Electric Group’s share price has moved to HK$3.02 after a 1-day share price return of 5.23%, yet the 90-day share price return is down 20.94% while the 3-year total shareholder return of 70.39% shows a...

Everest Medicines stock reacts to new cooperation framework Everest Medicines (SEHK:1952) drew fresh attention after its China subsidiary signed a multi year Strategic Cooperation Framework Agreement with Hasten Biopharmaceutical to coordinate supply, distribution, manufacturing and commercialization of selected products across the PRC. The new agreement comes after a choppy run for Everest Medicines, with the share price up 4.71% over the last day and 2.83% over the past week, yet still down...

Hengan International Group (SEHK:1044) has reshuffled its senior leadership, with veteran finance executive Li Wai Leung returning as executive director, chief financial officer and authorized representative, effective 9 September 2026. That leadership reshuffle lands at a tricky moment for Hengan International Group, with the share price at HK$19.70 after a 30 day share price return that fell 13.22% and a 1 year total shareholder return that declined 17.08%, signalling fading momentum rather...

China Longyuan Power Group (SEHK:916) just reported August 2026 operating data, with total power generation up 6.35% year on year and solar output advancing 20.67%, even as cumulative 2026 volumes remain slightly lower. For context, China Longyuan Power Group’s 1-day share price return of 2.42% to HK$5.285 comes after a year to date share price decline of 21.82% and a 1-year total shareholder return that is down 29%. This suggests recent operational updates may be starting to stabilise...

WuXi XDC Cayman announced that Ona Therapeutics has obtained an exclusive global license to the WuXiTecan-2 payload-linker platform for one antibody drug conjugate, with WuXi XDC also providing chemistry, manufacturing and controls support plus potential upfront, milestone and royalty revenues. The new out-licensing deal, the second ADC collaboration between WuXi XDC and Ona in two years, points to recurring client demand for WuXi XDC’s proprietary linker payload capabilities and deeper...

Chinasoft International (SEHK:354) has secured a RMB 35.5 million Foshan project tied to Guangdong’s Industrial Robot and Smart Home Application Enablement Centre, advancing its push into AI powered device edge cloud solutions for pan home furnishing manufacturers. Recent trading suggests investors are reassessing Chinasoft International’s prospects, with a 1-day share price return of 5.99% and a 90-day share price gain of 20.06%. However, the year to date share price return is down 24.76%...